Literature DB >> 23212805

Toward a guided approach to platelet activation in diabetes.

M D Linden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23212805     DOI： 10.1007/s11239-012-0852-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  10 in total

1.  Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.

Authors:  Michael Pignone; Mark J Alberts; John A Colwell; Mary Cushman; Silvio E Inzucchi; Debabrata Mukherjee; Robert S Rosenson; Craig D Williams; Peter W Wilson; M Sue Kirkman
Journal:  Circulation       Date:  2010-05-27       Impact factor: 29.690

2.  The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes.

Authors:  B Rocca; F Santilli; D Pitocco; L Mucci; G Petrucci; E Vitacolonna; S Lattanzio; D Mattoscio; F Zaccardi; R Liani; N Vazzana; A Del Ponte; E Ferrante; F Martini; C Cardillo; R Morosetti; M Mirabella; G Ghirlanda; G Davì; C Patrono
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

3.  Indices of platelet activation and the stability of coronary artery disease.

Authors:  M D Linden; M I Furman; A L Frelinger; M L Fox; M R Barnard; Y Li; K Przyklenk; A D Michelson
Journal:  J Thromb Haemost       Date:  2007-02-26       Impact factor: 5.824

4.  Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications.

Authors:  Galia Spectre; Lisa Arnetz; Claes-Göran Östenson; Kerstin Brismar; Nailin Li; Paul Hjemdahl
Journal:  Thromb Haemost       Date:  2011-07-28       Impact factor: 5.249

5.  Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo").

Authors:  David Vivas; Juan C García-Rubira; Esther Bernardo; Dominick J Angiolillo; Patricia Martín; Alfonso Calle-Pascual; Iván Núñez-Gil; Carlos Macaya; Antonio Fernández-Ortiz
Journal:  Heart       Date:  2011-03-04       Impact factor: 5.994

6.  Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.

Authors:  Davide Capodanno; Aasita Patel; Kodlipet Dharmashankar; José Luis Ferreiro; Masafumi Ueno; Murali Kodali; Salvatore D Tomasello; Piera Capranzano; Naveen Seecheran; Andrew Darlington; Antonio Tello-Montoliu; Bhaloo Desai; Theodore A Bass; Dominick J Angiolillo
Journal:  Circ Cardiovasc Interv       Date:  2011-03-08       Impact factor: 6.546

Review 7.  Overcoming aspirin treatment failure in diabetes.

Authors:  Matthew D Linden; Huyen A Tran
Journal:  Crit Rev Clin Lab Sci       Date:  2012-10-24       Impact factor: 6.250

8.  Influence of HbA1c levels on platelet function profiles associated with tight glycemic control in patients presenting with hyperglycemia and an acute coronary syndrome. A subanalysis of the CHIPS Study ("Control de HIperglucemia y Actividad Plaquetaria en Pacientes con Síndrome Coronario Agudo").

Authors:  David Vivas; Juan C García-Rubira; Esther Bernardo; Dominick J Angiolillo; Patricia Martín; Alfonso Calle-Pascual; Iván Núñez-Gil; Carlos Macaya; Antonio Fernández-Ortiz
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

9.  Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.

Authors:  Renda Soylemez Wiener; Daniel C Wiener; Robin J Larson
Journal:  JAMA       Date:  2008-08-27       Impact factor: 56.272

10.  Prognostic value of admission plasma glucose and HbA in acute myocardial infarction.

Authors:  S Hadjadj; D Coisne; G Mauco; S Ragot; F Duengler; P Sosner; F Torremocha; D Herpin; R Marechaud
Journal:  Diabet Med       Date:  2004-04       Impact factor: 4.359
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.